Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study.

Yoon-Koo Kang,Suzanne George,Robin L. Jones,Piotr Rutkowski,Lin Shen,Olivier Mir,Shreyaskumar Patel,Yongjian Zhou,Margaret von Mehren,Peter Hohenberger,Victor M. Villalobos,Mehdi Brahmi,William D. Tap,Jonathan C. Trent,Maria Abbondanza Pantaleo,Patrick Schöffski,Kevin He,Paggy Hew,Kate J. Newberry,Maria Roche,Michael Heinrich,Sebastian Bauer

Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study.

2021

PURPOSEPrimary or secondary mutations in KIT or platelet-derived growth factor receptor alpha (PDGFRA) underlie tyrosine kinase inhibitor resistance in most GI stromal tumors (GISTs). Avapritinib s...

Keywords:

Cancer research
Regorafenib
Stromal tumor
Medicine
Growth factor receptor
Tyrosine-kinase inhibitor
locally advanced
Stromal cell
Alpha (ethology)
PDGFRA

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations